In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Frailty and prognosis in heart failure. A prospective study with a quick and self-administered scale.

Session Poster Session 1

Speaker Juan Diego Sanchez Vega

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure – Epidemiology, Prognosis, Outcome
  • Session type : Poster Session

Authors : J Sanchez Vega (Madrid,ES), GL Alonso Salinas (Madrid,ES), S Del Prado Diaz (Madrid,ES), JM Vieitez Florez (Madrid,ES), E Gonzalez Ferrer (Madrid,ES), JL Zamorano (Madrid,ES)

Authors:
J Sanchez Vega1 , GL Alonso Salinas1 , S Del Prado Diaz1 , JM Vieitez Florez1 , E Gonzalez Ferrer1 , JL Zamorano1 , 1University Hospital Ramon y Cajal de Madrid, Cardiology - Madrid - Spain ,

Citation:

Background
Heart failure and its associated comorbidities are a delicate health condition that affects both life expectancy and the quality of life of patients. It is necessary to provide questionnaires or scales to stratify the short-term prognosis to address the need of medical attention or to know the death risks. Nowadays, we have scales like the Barcelona Bio-Heart Failure Risk Calculator (BioHF) or the Heart Failure Risk Calculator from MAGGIC investigation group, but its practical utility can be doubtful, due to the difficulties in completing these scales quickly in a consult setting. FRAIL scale has demonstrated a useful tool to detect frail patients at risk of suffering functional impairment, disability or death.

Material and methods
We proceeded to recruit a consecutive sample from the Advanced Heart Failure consults. After all participants signed the informed consent, patients completed FRAIL scale a few minutes before their medical consult. A total of 42 patients were recruited. Following, we analyzed the number of hospital re-entry in relation to acute hearth failure and death, in a period of six months from the first contact, dividing the patients in two groups: frail patients (3 or more points in FRAIL scale) and non frail patients. There were no significant diferences in sex, age and comorbidities between both groups. We compared the results in these groups with the score of the BioHF scale without biomarkers.

Results
Compared with non frail patients, the patients with 3 or more points in the scale presented higher rates of hospital ingress due to acute heart failure (33,3% vs 6,9%, p=0,003) and decease (16,7% vs 0%, p=0,024). The prognosis value of FRAIL scale was correlated with the score of the BioHF scale: in the one-year ingress, frail patients presented a bioHF score of 0,93% (vs 0,69 in non frail patients, p=0,044) and in death a BioHF of 32,5% (vs 17,1%, p=0,019).

Conclusions
FRAIL scale has demonstrated in our study to be a useful, simple and fast acquiring tool to assess the risk of hospital re-entry and short-term mortality in patients with heart failure.

Results Following Risk Stratification After 6 Months

VARIABLES

NON FRAIL(N=29)

FRAIL

(N=12)

p

Acute heart failure hospital re-entry

2 (6,9%)

4(33,3%)

0,003

Death

0(0%)

2(16,7%)

0,024

BioHF one year hospital re-entry(%)

0,69; 0,1

0,93; 0,2

0,044

BioHF one year death(%)

17,1; 2,9

32,5; 7,1

0,019

The number of hospital re-entry and deaths are presented as absolute values and percentages. Values of BioHF scale are presented as mean and standard deviation.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are